Lantheus Holdings Inc (LNTH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Lantheus Holdings Inc stock (LNTH) is currently trading at $74.24. Lantheus Holdings Inc PE ratio is 22.41. Lantheus Holdings Inc PS ratio (Price-to-Sales) is 3.29. Analyst consensus price target for LNTH is $91.38. WallStSmart rates LNTH as Hold.
- LNTH PE ratio analysis and historical PE chart
- LNTH PS ratio (Price-to-Sales) history and trend
- LNTH intrinsic value — DCF, Graham Number, EPV models
- LNTH stock price prediction 2025 2026 2027 2028 2029 2030
- LNTH fair value vs current price
- LNTH insider transactions and insider buying
- Is LNTH undervalued or overvalued?
- Lantheus Holdings Inc financial analysis — revenue, earnings, cash flow
- LNTH Piotroski F-Score and Altman Z-Score
- LNTH analyst price target and Smart Rating
Lantheus Holdings Inc
📊 No data available
Try selecting a different time range
LNTH Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Lantheus Holdings Inc (LNTH)
LNTH trades 190% above its Graham fair value of $23.19, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Lantheus Holdings Inc (LNTH) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, return on equity, profit margin. Concerns around revenue growth and eps growth. Fundamentals are solid but monitor weak areas for improvement.
Lantheus Holdings Inc (LNTH) Key Strengths (5)
Growing significantly faster than its price suggests
110.09% of shares held by major funds and institutions
Every $100 of equity generates $21 in profit
Strong profitability: $15 kept per $100 revenue
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Lantheus Holdings Inc (LNTH) Areas to Watch (5)
Earnings declining -77.10%, profits shrinking
Revenue growing slowly at 4.00% annually
Premium pricing at 4.5x book value
Decent operational efficiency, solid but not exceptional
Revenue is fairly priced at 3.29x sales
Lantheus Holdings Inc (LNTH) Detailed Analysis Report
Overall Assessment
This company scores 60/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 5 register as strengths (avg 8.8/10) while 5 fall into concern territory (avg 3.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Institutional Own., Return on Equity. Valuation metrics including PEG Ratio (0.61) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 21.40%, Profit Margin at 15.10%.
The Bear Case
The primary concerns are EPS Growth, Revenue Growth, Price/Book. Some valuation metrics including Price/Sales (3.29), Price/Book (4.53) suggest expensive pricing. Growth concerns include Revenue Growth at 4.00%, EPS Growth at -77.10%, which may limit upside. Profitability pressure is visible in Operating Margin at 19.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 21.40% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 4.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Institutional Own.) and negatives (EPS Growth, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
LNTH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
LNTH's Price-to-Sales ratio of 3.29x trades 18% below its historical average of 4.02x (40th percentile). The current valuation is 74% below its historical high of 12.71x set in Aug 2022, and 647% above its historical low of 0.44x in Mar 2016. Over the past 12 months, the PS ratio has compressed from ~4.2x as trailing revenue scaled faster than the stock price.
Compare LNTH with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Lantheus Holdings Inc (LNTH) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Lantheus Holdings Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 1.5B with 400% growth year-over-year. Profit margins of 15.1% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 400% YoY, reaching 1.5B. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
ROE of 2140.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Earnings fell 77% YoY while revenue grew 400%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Growth sustainability: can Lantheus Holdings Inc maintain 400%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Lantheus Holdings Inc.
Bottom Line
Lantheus Holdings Inc offers an attractive blend of growth (400% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(17 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:25:24 AM
About Lantheus Holdings Inc(LNTH)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Lantheus Holdings, Inc. develops, manufactures and markets diagnostic and therapeutic agents and products that assist physicians in the diagnosis and treatment of heart, cancer and other diseases worldwide. The company is headquartered in North Billerica, Massachusetts.